Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberculosis, Multidrug-Resistant
Conditions
Tuberculosis, Multidrug-Resistant
Trial Timeline
Jun 7, 2022 → May 31, 2027
NCT ID
NCT03828201About Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid
Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid is a phase 2 stage product being developed by Novartis for Tuberculosis, Multidrug-Resistant. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03828201. Target conditions include Tuberculosis, Multidrug-Resistant.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03828201 | Phase 2 | Recruiting |
Competing Products
20 competing products in Tuberculosis, Multidrug-Resistant